FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ildstad Suzanne						Issuer Name and Ticker or Trading Symbol     Talaris Therapeutics, Inc. [ TALS ]      Date of Earliest Transaction (Month/Day/Year)										Relationship of Repo (Check all applicable)     X Director  Officer (clius title)			10%	Owner	
(Last)	,	,	(Middle)					icol II	u130	actiUl	i (iviOi	ia // Day/ Teal	Officer (give tit below)			ie	below	(specify ()			
C/O TALARIS THERAPEUTICS, INC.  570 S. PRESTON ST.  (Street)  LOUISVILLE KY 40202					4. If Amendment, Date of Original Filed (Month/Day/Year)										Line)	. Individual or Joint/Group Filing (Check Applicatine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)							Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	1 - 1	Non-Derivat	ive	Secu	ıriti	es A	cqu	uire	d, Di	isposed (	of, or	Benefi	ciall	y Owr	ned				
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Yea	ır) E	2A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Code (Instr.		4. Securities Acquired ( Disposed Of (D) (Instr. 3			d 5)	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Cod	le	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	ction(s)	ľ		,	
Common Stock			06/05/2023					S	5		7,841	D	\$2.519	<b>)</b> 4 <sup>(1)</sup>	2,782,023		D				
Common Stock				06/06/2023					S			25,549	D	\$2.5283 <sup>(2)</sup>		2,756,474		D			
Common	Stock															1,20	0,000		I	by GRAT	
Common Stock																654	1,205		I	See footnote <sup>(3)</sup>	
Common Stock																654	1,205		I	See footnote <sup>(4)</sup>	
		Tal	ble	II - Derivativ (e.g., put												Owne	d				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any					saction e (Instr.	Of Di Sc Ac (A Di of (I)	umber	ve es d	Expir	ation	ercisable and Date //Year)	Amo Secu Undo Deriv Secu	r. 3 and 4)	De Se (In:	rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code V (A) (D				Date Exerc	cisable	Expiration e Date	n Title	Amount or Number of Shares								

## Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.46 to \$2.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.44 to \$2.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 4. These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

## Remarks:

/s/ Mary Kay Fenton, attorney-in-fact

06/07/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.